Research and Deployment of a quantum mechanical NMR tool for fragment based drug

用于基于片段的药物的量子力学核磁共振工具的研究和部署

基本信息

批准号：
8721497
负责人：
Lance M Westerhoff
金额：
$ 13.04万
依托单位：
QUANTUMBIO, INC.
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-06-01 至 2016-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8721497
关键词：
Academia Active Sites Address Algorithms Amides Area Binding Biological Boxing Chemicals Complex Computer software Data Databases Development Disease Docking Drug Design Drug Interactions Future Goals Grant Growth Health Homology Modeling Human Industry Investments Lead Letters Ligand Binding Ligands Mainstreaming Marketing Measures Mechanics Membrane Proteins Methodology Methods Mission Molecular Nuclear Magnetic Resonance Performance Pharmaceutical Preparations Pharmacologic Substance Phase Play Population Positioning Attribute Preparation Price Process Proteins Relative (related person)Research Research Personnel Role Scoring Method Services Small Business Innovation Research Grant Solubility Structure Technology Time Training United States National Institutes of Health Ursidae Family Validation Work X-Ray Crystallography base density design drug candidate drug development drug discovery graphical user interface human disease improved insight interest next generation novel therapeutics phase 1 study phase 2 study product development protein structure quantum receptor research study small molecule solid state nuclear magnetic resonance success theories tool validation studies

项目摘要

DESCRIPTION (provided by applicant): Improving human health by enabling the development of drugs faster and cheaper is an important part of the NIH mission. This is partially achieved by introducing and constantly improving enabling technologies. One such technology is structure based drug design. Determining the structure of a small molecule (drug candidate or lead compound) to a biological receptor (protein implicated in disease) is a necessary step in this methodology. The dominant experimental approach used to achieve this goal is X- ray crystallography, while nuclear magnetic resonance (NMR) plays a lesser role in spite of large investments both in academia and industry. NMR is hampered by the size of protein that can be studied and the need to go through a lengthy structure determination process. However, with the advent of fragment based drug design, NMR is playing a much larger role and it could play an even greater role if it was possible to reduce the time effort necessary to solve the structure of a protein-ligand complex. Moreover, in cases where it is not possible to obtain a crystal NMR can play a significant role. Through the use of solid-state NMR studies membrane proteins or proteins with solubility problems can be studied or in cases where only homology models of a protein are available NMR could play a role through the validation of active site structure hypotheses generated in homology modeling studies. The aim of the proposed research is to extend and commercialize QuantumBio's successful linear-scaling semiempirical quantum mechanical NMR approach (NMRScore) to chemical shift perturbation (CSP) analysis through the addition of target-observed CSP and ab initio NMR methods. In Phase I of this proposal the limits of applicability will be explored. In the Phase II proposal extension of the methodology via reparameterization of 1H, 13C 17O and 15N NMR will be carried out and a new classical NMR predictor will be developed. Furthermore, the streamlining of the workflow will be researched and implemented. Finally, this proposal is aiming to fully productize and commercialize this breakthrough technology. It is anticipated that by making this application commercially available the use of NMR in structure-based design efforts will be enhanced and the NMR tool and service market size can be further expanded. Significantly, the tool-box of structure based drug design will gain an important new method which will enable drug development for targets inaccessible to today's mainstream drug discovery paradigm. Thus, in the near future important underserved diseases can be targeted more efficiently.

描述（由申请人提供）：通过更快、更便宜地开发药物来改善人类健康是 NIH 使命的重要组成部分。这部分是通过引入和不断改进支持技术来实现的。其中一项技术是基于结构的药物设计。确定小分子（候选药物或先导化合物）与生物受体（与疾病有关的蛋白质）的结构是该方法中的必要步骤。用于实现这一目标的主要实验方法是 X 射线晶体学，而核磁共振 (NMR) 尽管在学术界和工业界都投入了大量资金，但发挥的作用较小。核磁共振技术受到可研究蛋白质大小的限制，并且需要经历漫长的结构测定过程。然而，随着基于片段的药物设计的出现，NMR 正在发挥更大的作用，如果可以减少解析蛋白质-配体复合物结构所需的时间，那么它可以发挥更大的作用。此外，在无法获得晶体的情况下，NMR 可以发挥重要作用。通过使用固态 NMR 研究，可以研究膜蛋白或具有溶解度问题的蛋白质，或者在只有蛋白质同源模型可用的情况下，NMR 可以通过验证同源建模研究中生成的活性位点结构假设发挥作用。拟议研究的目的是通过添加目标观测 CSP 和从头算 NMR 方法，将 QuantumBio 成功的线性缩放半经验量子力学 NMR 方法 (NMRScore) 扩展到化学位移扰动 (CSP) 分析，并将其商业化。在该提案的第一阶段，将探讨适用性的限制。在第二阶段提案中，将通过重新参数化 1H、13C、17O 和 15N NMR 来扩展该方法，并开发新的经典 NMR 预测器。此外，还将研究并实施工作流程的简化。最后，该提案旨在将这一突破性技术完全产品化和商业化。预计通过将该应用商业化，NMR 在基于结构的设计工作中的使用将得到加强，并且 NMR 工具和服务市场规模将进一步扩大。值得注意的是，基于结构的药物设计工具箱将获得一种重要的新方法，该方法将使药物开发能够针对当今主流药物发现范式无法达到的目标进行药物开发。因此，在不久的将来，可以更有效地针对重要的服务不足的疾病。